In a post hoc analysis of CHAMPION PHOENIX, patients with more complex lesions had higher periprocedural thrombotic event rates, and the absolute benefit of KENGREAL increased progressively with the number of high-risk lesions treated.1
Blinded angiographic core laboratory analysis was completed in 10,854 of the 10,942 (99.2%) randomized modified intention-to-treat patients in CHAMPION PHOENIX (13,418 target lesions).
PCI patients with high-risk characteristics can differ in disease severity and comorbidities, and not all high-risk lesion characteristics were accounted for in the present analysis. Treatment protocols should account for individualization of care as KENGREAL may not be appropriate for some patients.
95% confidence intervals appear under each rate estimate in parentheses.
*MACE is the measure of death, MI, ischemia-driven revascularization, or ST.
†Comparison between 0 and ≥3 high-risk features.
This is a post hoc analysis and presents findings that supplement the predefined primary results of the CHAMPION PHOENIX trial. The CHAMPION PHOENIX trial was not designed nor powered to examine the impact of KENGREAL and clopidogrel on specific angiographic risk characteristics, lesion types, and outcomes.
KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.
KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.
The most common adverse reaction is bleeding.
KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.